Elevation Oncology (ELEV) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Elevation Oncology (NASDAQ: ELEV):

• 3/24/2025 – Elevation Oncology had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $1.00 price target on the stock, down previously from $5.00.
• 3/21/2025 – Elevation Oncology was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating. They now have a $0.70 price target on the stock, down previously from $10.00.
• 3/21/2025 – Elevation Oncology was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $1.00 price target on the stock, down previously from $9.00.
• 3/21/2025 – Elevation Oncology was downgraded by analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating.
• 3/21/2025 – Elevation Oncology had its price target lowered by analysts at HC Wainwright from $6.00 to $1.00. They now have a “buy” rating on the stock.
• 3/20/2025 – Elevation Oncology was downgraded by analysts at Wedbush from a “strong-buy” rating to a “hold” rating.
• 3/20/2025 – Elevation Oncology was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 3/10/2025 – Elevation Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 3/7/2025 – Elevation Oncology had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $5.00 price target on the stock.
• 3/7/2025 – Elevation Oncology had its “outperform” rating reaffirmed by analysts at William Blair. They now have a $5.00 price target on the stock.

Elevation Oncology Price Performance

Shares of ELEV opened at $0.28 on Wednesday. The business has a 50-day moving average of $0.58 and a 200-day moving average of $0.59. Elevation Oncology, Inc. has a 1 year low of $0.24 and a 1 year high of $5.83. The company has a market capitalization of $16.76 million, a price-to-earnings ratio of -0.35 and a beta of 1.37. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. As a group, equities research analysts anticipate that Elevation Oncology, Inc. will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On Elevation Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Velan Capital Investment Management LP acquired a new stake in Elevation Oncology in the fourth quarter valued at approximately $25,000. Bank of America Corp DE grew its position in Elevation Oncology by 42.5% in the 4th quarter. Bank of America Corp DE now owns 56,839 shares of the company’s stock valued at $32,000 after purchasing an additional 16,962 shares during the period. JPMorgan Chase & Co. increased its stake in Elevation Oncology by 175.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock valued at $37,000 after purchasing an additional 39,101 shares in the last quarter. SG Americas Securities LLC raised its holdings in Elevation Oncology by 33.9% during the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock worth $35,000 after buying an additional 15,560 shares during the last quarter. Finally, Two Sigma Securities LLC bought a new position in shares of Elevation Oncology in the fourth quarter valued at $35,000. 83.70% of the stock is owned by institutional investors.

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.